Abstract: The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.

Abstract: A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.

Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.

Abstract: Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.

Abstract: The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Abstract: The present invention provides, in some embodiments, multi-layer silk compositions including a first layer comprising silk fibroin and keratinocytes, a second layer comprising silk fibroin and fibroblasts, a third layer comprising silk fibroin and adipocytes, and a plurality of nervous system cells, wherein at least some of the plurality of nervous system cells span at least two layers, and methods of making and using the same. In some embodiments, provided methods and compositions further include immune cells and/or endothelial cells.

Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.

Abstract: Provided is a method for preparing a sugar chain, including: a labeling step of adding a labeling reagent to a sugar chain-containing sample which contains a sugar chain to obtain a labeled product containing a labeled substance of the sugar chain, in which a reaction environment of the labeling reagent and the sugar chain contains water in the labeling step.

Abstract: Embodiments of the present invention relate generally to processes, systems, and compositions useful in manipulating a ratio of viable X chromosome bearing sperm to viable Y chromosome bearing sperm in at least one sperm population and useful for preserving the resulting manipulated sperm population. In some embodiments a cryoprotectant may be incorporated into various medias used in manipulating the sperm sample, such as in a staining media, a sheath fluid, and a collection media.

Abstract: The present invention describes in vitro methods for producing a cellular composition with in vivo bone forming potential.

Abstract: Compositions and methods for a hybrid biological and chemical process that captures and converts carbon dioxide and/or other forms of inorganic carbon and/or CI carbon sources including but not limited to carbon monoxide, methane, methanol, formate, or formic acid, and/or mixtures containing CI chemicals including but not limited to various syngas compositions, into organic chemicals including biofuels or other valuable biomass, chemical, industrial, or pharmaceutical products are provided. The present invention, in certain embodiments, fixes inorganic carbon or CI carbon sources into longer carbon chain organic chemicals by utilizing microorganisms capable of performing the oxyhydrogen reaction and the autotrophic fixation of CO2 in one or more steps of the process.

Abstract: A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on he severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.

Abstract: Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.

Abstract: Provided is a method for separating and extracting mesenchymal stem cells from the human umbilical cord. The method uses healthy neonatal umbilical cord tissue; after cleaning and disinfection, mechanically pulverising same, separating the Wharton's jelly, and after treating with erythrocyte lysate, carrying out suspension culture in a serum-free culture medium. Replacing the liquid every 3-5 days; after the plate adherence rate reaches 30-70%, carrying out trypsin digestion, and then collecting the cells by centrifugation for passage amplification, until the rate of confluence of the cells reaches 80-90% confluence, thereby obtaining high purity umbilical cord mesenchymal stem cells.

Abstract: The present invention provides a method for determining whether or not a sample contains at least one of Cercospora fungus and Pseudocercospora fungus. In the method, first, the sample is added an aqueous solution containing N,N,N?,N?-Tetramethyl-1,4-phenylenediamine and 5-(2,4-disulfophenyl)-3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-tetrazolium to provide a mixture. The aqueous solution has a pH of not less than 5.1 and not more than 6.5. Then, the mixture is irradiated with light having a wavelength of 400 to 500 nanometers to measure a first absorbance Ay of the mixture, and the mixture is irradiated with light having a wavelength of 500 to 800 nanometers to measure a second absorbance Ax of the mixture. If the value of Ay/Ax is not less than 1.5 or the mixture is orangey, it is determined that the sample contains at least one of Cercospora fungus and Pseudocercospora fungus.

Abstract: The present invention provides methods of processing lipid materials such as soapstock, wet gums and dry gums. Enzymes are utilized to catalyze hydrolysis of the lipids materials to recover fatty acids. Addition of organic acids and/or polyols improved yield of fatty acids and reduced formation of emulsion. Lipid materials can be formulated with other agricultural products as new value-added animal feed products. Further, a process for concentrating nitrogenous compounds such as choline, inositol, ethanolamine and serine from phospholipid materials obtained as byproducts from vegetable oil refining is provided. The process involves performing hydrolysis of the gum based products in the presence of an alcoholic solvent and acid catalyst. Post hydrolysis, gums breakdown to oil and water phases which are further separated and concentrated. These concentrated products may be further fractionated to concentrate individual nitrogenous compounds.

Abstract: The presently disclosed subject matter provides a microfluidic device that can simulate capillary blood flow on a fetal side of the device and pooled blood on a maternal side of the device (i.e., intervillous space). The microfluidic device can reconstitute the maternal-fetal interface, can expand the capabilities of cell culture models, and can provide an alternative to current maternal-fetal transfer models.

Abstract: A method and apparatus for enzymatic hydrolysis where a plant based feed is hydrolysed using an enzyme to form a hydrolysed product. An additive for preventing enzyme adsorption is fed to an enzymatic hydrolysis stage, the plant based feed, the hydrolysed product, a starting material, and/or a plant based material formed from the starting material. The hydrolysed product is supplied from the enzymatic hydrolysis stage to a first solid-liquid separation stage where a lignin fraction comprising the additive and a liquid composition comprising the enzyme are separated. The liquid composition is mixed with the plant based material in a mixing stage, forming a mixture. A solid and liquid fraction are separated from the mixture in a second solid-liquid separation stage. At least part of the solid fraction comprising the enzyme is fed as the plant based feed to the enzymatic hydrolysis stage.

Abstract: The present invention is a method for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium.